摘要
目的:比较格列齐特缓释片与格列齐特的临床降糖效果及对血浆胰岛素水平的影响。方法:选择服用格列齐特或合用阿卡波糖或二甲双胍的2型糖尿病患者,血糖控制良好,治疗方案至少恒定2个月,共30例,随机分为两组,各15例,1组继续原有治疗;1组将格列齐特改为相应剂量的格列齐特缓释片,观察12周,前后检测基本临床生化指标及糖化血红蛋白, 并在观察的第1天和最后1天安排2次住院,每次24小时,检测不同点血糖和胰岛素水平。结果:格列齐特缓释片与格列齐特的临床降糖效果及对血浆胰岛素水平的影响无明显差异。结论:格列齐特缓释片与普通片同样具有降糖效果可靠、作用持久、稳定,但1日1次,服药方便,是便于患者应用的口服降糖药。
Objective:To compare the effects of diamicron MR and gliclazide on blood glucose and plasma insulin levels in type 2 diabetes.Methods: 30 cases of type 2 diabetic patients were assigned to two groups randomly. One group (n = 15) was treated with diamicron MR, and other group (n=15) was treated with gliclazide. All cases were followed up 12 weeks. BMI, blood pressure, HbAlc, blood lipid, plasma insulin and glucose of 24hr were measured before and after the therapy. Results: There were no significant differences between two group. Conclusion: Diamicron MR is a safe sulfonylurea praeparatum. It has a long and steady antidiabetic effect, also a good tolerant profile.
出处
《中国医药导刊》
2005年第3期192-193,共2页
Chinese Journal of Medicinal Guide
